Windlas Biotech Limited - Asset Resilience Ratio
Windlas Biotech Limited (WINDLAS) has an Asset Resilience Ratio of 32.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Windlas Biotech Limited balance sheet assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Windlas Biotech Limited's Asset Resilience Ratio has changed over time. See WINDLAS equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Windlas Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Windlas Biotech Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.61 Billion | 32.06% |
| Total Liquid Assets | Rs2.61 Billion | 32.06% |
Asset Resilience Insights
- Very High Liquidity: Windlas Biotech Limited maintains exceptional liquid asset reserves at 32.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Windlas Biotech Limited Industry Peers by Asset Resilience Ratio
Compare Windlas Biotech Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Windlas Biotech Limited (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Windlas Biotech Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 31.54% | Rs2.40 Billion ≈ $25.94 Million |
Rs7.60 Billion ≈ $82.24 Million |
-0.25pp |
| 2024-03-31 | 31.79% | Rs1.99 Billion ≈ $21.53 Million |
Rs6.26 Billion ≈ $67.72 Million |
+7.54pp |
| 2023-03-31 | 24.25% | Rs1.28 Billion ≈ $13.87 Million |
Rs5.29 Billion ≈ $57.21 Million |
-11.48pp |
| 2022-03-31 | 35.73% | Rs1.75 Billion ≈ $18.97 Million |
Rs4.91 Billion ≈ $53.10 Million |
+22.79pp |
| 2021-03-31 | 12.94% | Rs383.25 Million ≈ $4.14 Million |
Rs2.96 Billion ≈ $32.02 Million |
+6.27pp |
| 2020-03-31 | 6.67% | Rs225.86 Million ≈ $2.44 Million |
Rs3.38 Billion ≈ $36.61 Million |
-0.45pp |
| 2019-03-31 | 7.12% | Rs212.41 Million ≈ $2.30 Million |
Rs2.98 Billion ≈ $32.25 Million |
-0.76pp |
| 2018-03-31 | 7.88% | Rs228.53 Million ≈ $2.47 Million |
Rs2.90 Billion ≈ $31.35 Million |
-- |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more